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Fast and simple hydrophilic interaction liquid chromatography (HILIC) method was developed and validated for the analysis of
moxonidine and its four impurities (A, B, C, and D) in pharmaceutical dosage form. All experiments were performed on the
Agilent Technologies 1200 high-performance liquid chromatography (HPLC) system using Zorbax RX-SIL, 250mm × 4.6mm, 5 𝜇m
column as stationary phase (𝑇 = 25∘C, 𝐹 = 1mL/min, and 𝜆 = 255 nm), and mixture of acetonitrile and 40mM ammonium
formate buffer (pH 2.8) 80 : 20 (v/v) as mobile phase. Under the optimal chromatographic conditions, selected by central composite
design, separation and analysis of moxonidine and its four impurities are enabled within 12 minutes. Validation of the method was
conducted in accordance with ICH guidelines. Based on the obtained results selectivity, linearity (𝑟 ≥ 0.9976), accuracy (recovery:
93.66%–114.08%), precision (RSD: 0.56%–2.55%), and robustness of the method were confirmed. The obtained values of the limit
of detection and quantification revealed that the method can be used for determination of impurities levels below 0.1%. Validated
method was applied for determination of moxonidine and its impurities in commercially available tablet formulation. Obtained
results confirmed that validated method is fast, simple, and reliable for analysis of moxonidine and its impurities in tablets.
1. Introduction
Moxonidine belongs to the second generation of centrally
acting antihypertensive drugs that exhibit high binding
affinity for I1-imidazoline receptor and minor activity at 𝛼2-
adrenoceptors which explains the absence of adverse effects
characteristic for the first generation of antihypertensives
such as sedation and dry mouth. It is used in therapy as
antihypertensive as well as to improve metabolic profile of
patients with hypertension and diabetes type 2 or with an
impaired glucose tolerance [1].
The European Pharmacopoeia [2] and the British Phar-
macopoeia [3] list four related substances of moxonidine:
impurity A (4-chloro-moxonidine), impurity B (6-methoxy-
moxonidine), impurity C (4-hydroxy-moxonidine), and
impurity D (4-hydroxy-6-chloro-moxonidine). Structures
of moxonidine and its impurities are shown in Figure 1.
Official method in Pharmacopoeia for the determination
of moxonidine and its four impurities is high-performance
liquid chromatography (HPLC) based on octylsilyl silica
particles as a stationary phase and the ion-pair reagents as
a component of the mobile phase. From the chemical point
of view moxonidine and its impurities are weak bases with
nitrogen ionizable center which can be protonated. These
molecules are completely ionized in an acidic medium [4]
and do not have a high affinity for apolar stationary phase.
In order to avoid the application of ion-pair reagent which
enables adequate retention of compounds or micellar liquid
chromatography (MLC) which is suitable for simultaneous
determination of ionic and nonionic compounds [5, 6], anal-
ysis of ionized molecules can be performed by hydrophilic
interaction liquid chromatography (HILIC) method. This
method is described as a useful alternative to reverse phase
chromatography in which the polar columns, such as silica
and amino, are used as the stationary phase and water/buffer
solution with high volume ratio of an organic solvent as a
mobile phase [7, 8].
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Figure 1: Chemical structures of moxonidine and its impurities.
Literature survey has revealed RP-HPLC method for
the determination of moxonidine in the presence of its
four impurities [9] while UPLC method based on nonpolar
stationary phase was used for separation and determination
of moxonidine, as well as for its degradation products, which
occur after the acidic, basic, or neutral hydrolysis, thermal
or photolytic degradation [10]. Moxonidine was separated
from its two impurities by thin layer chromatography (TLC)
method [11], and fast and simple TLC method for the
determination ofmoxonidine and its four impurities was also
conducted [12].
Apart from the reported HILIC method which was
applied for the separation of moxonidine and its five impu-
rities using an amino column as the stationary phase [7],
there are no HILIC reports available on the optimization of
HILIC condition and determination of moxonidine and its
four impurities using polar silica column. Thus, the main
objective of this study was to systematically examine the
retention behavior of moxonidine and its four impurities
in HILIC system by central composite design and then
under the optimized chromatographic conditions to validate
the method for the determination of moxonidine and its
four impurities in pharmaceutical dosage form according to
International Council on Harmonisation (ICH) guidelines
[13].
2. Materials and Methods
2.1. Reagents and Materials. Moxonidine (99.4% purity), 4-
chloro-N-(imidazolidin-2-ylidene)-6-methoxy-2-methyl-
pyrimidin-5-amine; impurity A (99.4% purity), 4,6-
dichloro-N-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-
amine (6-chloro-moxonidine); impurity B (98.5% purity),
N-(imidazolidin-2-ylidene)-4,6-dimethoxy-2-methylpyrim-
idin-5-amine (4-methoxy-moxonidine); impurity C (98.9%
purity), 5-[(imidazolidin-2-ylidene)amino]-6-methoxy-2-
methylpyrimidin-4-ol (4-hydroxy-moxonidine,); and
impurity D (97.79% purity), 6-chloro-5-[(imidazolidin-2-
ylidene)amino]-2-methylpyrimidin-4-ol (6-desmethyl-mox-
onidine), were obtained from Chemagis (Bnei Brak, Israel)
(Figure 1). The Moxogamma 0.4mg film tablets were
manufactured by Worwag Pharma (Bo¨blingen, Germany).
The purified water (TKA, GenPure, Niederelbert, Ger-
many), ammonium formate for HPLC ≥ 99.0% (Merck,
Darmstadt, Germany), formic acid 98–100% for analysis
(Merck, Darmstadt, Germany), and HPLC grade acetonitrile
≥ 99.93% (SigmaAldrich, Steinheim,Germany)were used for
the preparation of the mobile phase.
2.2. Chromatographic Conditions. Chromatographic analysis
was performed using an Agilent Technologies 1200HPLC
system (Santa Clara, CA, USA) consisting of a binary pump,
degasser, a thermostat for the column, and the photodiode
array detector. Samples were injected through a Rheodyne
injector valve with a 20 𝜇L sample loop. The analytical
column Zorbax RX-SIL, 250mm × 4.6mm, 5 𝜇m (Agilent
Technology, SantaClara, CA,USA)was used as the stationary
phase.Themobile phase consisted of amixture of acetonitrile
and 40mM ammonium formate buffer pH = 2.8 (80 : 20 v/v).
The column temperature (𝑇 = 25∘C), the flow rate of the
mobile phase (𝐹 = 1mL/min), and the wavelength (𝜆 =
255 nm) were kept constant during the analysis.
2.3. Experimental Design. The experimental scheme was
obtained by central composite rotable design using Design-
Expert 7.0.0 program (Stat-Ease, Minneapolis, MN, USA).
Based on the observation obtained during the preliminary
studies, three factors, that is, percent of acetonitrile in mobile
phase (𝑥1) examined at levels 70%, 75%, and 80%; pH of
the aqueous phase (𝑥2) examined at levels 2.8, 3.5 and 4.2;
and concentration of ammonium formate in aqueous phase
(𝑥3) examined at levels 20, 40, and 60mM were selected for
screening. The soft independent modeling of class analogy
SIMCA-P+ 12.0 program [14]was used for investigation of the
influence of the examined factors on the retention behavior of
the tested compounds. Retention factors of moxonidine and
its four impurities (𝑘M, 𝑘A, 𝑘B, 𝑘C, 𝑘D) and resolution between
impurities A and B, RsA/B, as well as impurities C and D,
RsC/D, were used as dependent variables 𝑌 while examined
factors and their interactions were used as independent
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variables𝑋 (𝑥1, 𝑥2, 𝑥3, 𝑥1 × 𝑥1, 𝑥2 × 𝑥2, 𝑥3 × 𝑥3, 𝑥1 × 𝑥2, 𝑥1 ×
𝑥3, 𝑥2 × 𝑥3) during PLS modeling.
2.4. Solutions
2.4.1. Preparation of Stock Solutions and Working Stan-
dard Solutions. The stock standard solutions of moxonidine
(1mg/mL), impurities A and B (0.05mg/mL), and impurities
C and D (0.01mg/mL) were prepared separately in mixture
of methanol-water (50 : 50 v/v). Stock solutions were further
diluted to obtain a mixture of 100 𝜇g/mL of moxonidine,
0.5 𝜇g/mL of impurities A and B, and 1.0 𝜇g/mL of impurities
C and D.
2.4.2. Preparation of Solutions for the Selectivity Estimation.
Placebo consisting of magnesium stearate, lactose monohy-
drate, povidone K-25, and crospovidone was prepared in
the concentration ratio corresponding to the content in the
Moxogamma 0.4 tablets. Prepared mixture was conducted
through the same procedure as the tablet mass used for
preparation of sample solution.
A standard solution mixture containing 100 𝜇g/mL of
moxonidine, 0.5 𝜇g/mL of impurities A and B, and 1.0 𝜇g/mL
of impurities C and D was used for estimation of the method
selectivity.
2.4.3. Preparation of Solutions for the Linearity Estimation.
For the calibration curves, stock solutions were diluted with
mobile phase in order to obtain nine solutions of impurities
in the concentration ranges of 0.04–0.6𝜇g/mL for impurities
A and B, 0.08–1.2 𝜇g/mL for impurities C and D, and six
solutions containing moxonidine in the range 25–150 𝜇g/mL.
2.4.4. Preparation of the Solutions for the Accuracy and
Precision Estimation. Solutions for the method accuracy and
precision estimation were prepared by spiking placebo with
moxonidine at concentration levels 80%, 100%, and 120% as
well as with moxonidine and impurities A, B, C, and D at
concentration levels corresponding to LOQ, 100% and 120%.
Solutions were prepared by mixing 0.25 g of placebo with
appropriate volumes of stock solutions in 10mL volumetric
flasks. After addition of 5mL of mobile phase, solutions were
treated on ultrasonic bath for 10 minutes and diluted with the
mobile phase to volume. The resulting solutions were cen-
trifuged at 3000 rpm for 15min and then the supernatant was
separated and filtered through a membrane filter (0.45 𝜇m).
For each concentration level three solutions were prepared.
2.4.5. Sample Preparation. Twenty tablets from which the
film had previously been removed were weighted and pul-
verized. The amount of the tablet mass containing 1mg of
moxonidine was dissolved in 5mL of mobile phase in 10mL
volumetric flask, sonicated for 10min, dilutedwith themobile
phase to the volume, and centrifuged at 3000 rpm for 15min.
The obtained supernatant was separated and filtered through
a membrane filter (0.45 𝜇m).
3. Results and Discussion
3.1. Optimization of the Mobile Phase. Moxonidine and its
impurities contain guanidine function in which nitrogen
atom can be protonated; thus these compounds behave as
weak bases with calculated𝑝𝐾𝑎 values 7.92, 7.06, 7.48, 7.17, and
6.95 formoxonidine, impurity A, impurity B, impurity C, and
impurity D, respectively [4]. Under the acidic experimental
conditions (pH2.8) all the studied compounds are completely
ionized and exist in cationic forms with the charge +1.
In addition, these compounds exhibit similar polarity, with
calculated log𝑝 values 1.77, 2.49, 1.60, 1.57, and 2.01 for mox-
onidine, impurity A, impurity B, impurity C, and impurity
D, respectively [4]. Impurity A has the most pronounced
lipophilic properties due to the presence of 2 chlorine atoms.
According to increasing lipophilicity moxonidine and its
impurities can be represented in the following order: C <
B < moxonidine < D < A. Due to the similarity of the
analyzed compounds in structure and polarity the separation
of such compounds in a short period of time is a challenge for
the analysts. Thus, finding appropriate separation conditions
requires careful selection of a stationary and mobile phase.
For optimization of chromatographic condition hydrophilic
interaction liquid chromatography method using polar silica
column was applied.
Preliminary experiments showed that components of the
mobile phase such as content of acetonitrile, pH, and the con-
centration of the buffer are the factors influencing resolution
and retention behavior of examined compounds. Content
of acetonitrile in the mobile phase was investigated in the
range of 70% to 80%. Higher percents of acetonitrile were
associated with a significant extension of the analysis time,
whereas the smaller proportions were drastically reduced
resolution among the tested compounds. The range of the
tested pH values was set between 2.8 and 4.2.With increasing
pH value there was a significant prolongation of the retention
time of the observed compounds.The selected concentration
range of the buffer was from 20mM to 60mM. For the
assessment of an impact of selected factors on the retention
behavior of tested compounds central composite design was
selected with the total number of the experiments being 20,
with six experiments representing replications in the central
point. Retention factors of analyzed compounds and resolu-
tion between critical peak pairs (A/B and C/D) were followed
as the systems outputs.The experimental conditions designed
by the experimental plan are presented in Table 1. High values
of statistical parameters such as 𝑅2 (square of the correlation
coefficient) and 𝑄2 (cross-validated correlation coefficient)
obtained for created PLSmodels (Table 2) ensured their good
prognostic capacity.
The influence of the examined factors on the retention
and resolution is presented on the coefficients plots (Figures
2 and 3). On these plots, in which the regression coefficients
appear as bars and the confidence intervals at 95% confidence
limit as error lines, significance of different variables can
be seen. The variable is considered as insignificant if the
error line crosses the 𝑥-axis and the error is higher than the
regression coefficient bar. Coefficients on the upper side of
𝑥-axis have a positive impact on examined output variable,
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Table 1: Plan of experiments.
Exp.
number % ACN





1 75 3.5 40
2 75 3.5 40
3 75 3.5 40
4 75 3.5 40
5 75 3.5 40
6 75 3.5 40
7 70 2.8 20
8 80 2.8 20
9 70 4.2 20
10 80 4.2 20
11 70 2.8 60
12 80 2.8 60
13 70 4.2 60
14 80 4.2 60
15 66.59 3.5 40
16 83.41 3.5 40
17 75 2.32 40
18 75 4.68 40
19 75 3.5 6.36
20 75 3.5 73.64
while coefficients on the bottom side of 𝑥-axis have a negative
impact on examined output variable.
The coefficient plot (Figure 2) of the PLS (𝑘A) model indi-
cates that all significant variables (pH, pH × pH (nonlinear
effect), ACN × pH (interaction effect), pH × C (interaction
effect)) are in negative correlation with retention factor of
impurity A, while for all other tested compounds same
significant variables (ACN, ACN × ACN (nonlinear effect),
ACN× pH (interaction effect)) appeared as important factors
influencing their retention and were in positive correlation
with 𝑘B, 𝑘C, 𝑘D and 𝑘M (Figure 2).
Among individually tested components of mobile phase,
acetonitrile had the highest effect on the retention behavior
of moxonidine and impurities B, C, and D. Increasing the
content of acetonitrile leads to an increase values of retention
factors and to higher retention of substances on the column.
On the other hand, change in pH value was the most
important factor influencing the retention of impurity A
(Figure 2).
Statistically best models obtained when the resolution
between impurities A and B, RsA/B, as well as impurities C
and D, RsC/D, was followed as the responses were the PLS
models with the following statistical parameters: PLS (RsA/B):
𝑅2 = 0.897 and 𝑄2 = 0.833; PLS (RsC/D): 𝑅
2 = 0.802 and
𝑄2 = 0.71.
Upon examination of the coefficient plot of the PLS
models (Figure 3), the most important influences on the
resolution between critical peak pairs (impurities A and B)
Table 2: Statistical parameters of created PLS models.
PLS models 𝑅2 𝑄2
PLS (𝑘A) 0.648 0.584
PLS (𝑘B) 0.792 0.707
PLS (𝑘C) 0.983 0.964
PLS (𝑘D) 0.98 0.959
PLS (𝑘M) 0.81 0.731
PLS (RsA/B) 0.897 0.833
PLS (RsC/D) 0.802 0.71
were shown: ACN, pH, ACN × ACN (nonlinear effect),
ACN × pH (effect of interaction), and pH × pH (nonlinear
effect). All of these variables are in positive correlation with
RsA/B. The highest influence on resolution between peaks
C and D was shown: pH, pH × pH (nonlinear effect), and
ACN × pH (effect of interaction) and all were in negative
correlation with (RsC/D). Performed experiments revealed
that combination of lower percent of acetonitrile (70%) and
lower pH values (2.8) regardless of buffer concentration
leads to coelution of impurities A and B (RsA/B = 0), while
critical separation of impurities C and D (RsC/D = 0) has
been observed under pH values 4.68, 75% of acetonitrile,
and 40mM buffer.These critical experimental conditions for
impurities C and D were suitable for separation of impurities
A and B whose resolution was 10.91. Under the all examined
conditions given on Table 1 resolution between impurities A
and Bwas significantlymore sensitive to the changes of tested
factors compared to resolution between impurities C and
D. Finally, for the most examined experimental conditions
both critical resolutions were higher than 2, but detailed
analysis of the influence of various factors on the retention
behavior of the tested compounds revealed that the optimal
chromatographic conditions for the separation of moxoni-
dine and its four impurities can be achieved using a mobile
phase consisted of acetonitrile, 40mMbuffer solution, pH 2.8
(80 : 20 v/v) at a temperature of 25∘C, flow rate of 1mL/min,
and at a wavelength of 255 nm. The optimized method was
further validated in order to confirm its selectivity, linearity,
precision, accuracy, sensitivity, and robustness, as well as the
possibility for applying in determination of moxonidine and
its impurities in pharmaceutical dosage form.
3.2. Method Validation
3.2.1. Selectivity. The selectivity of the method was proved
by comparing the chromatograms of placebo mixture and
standard solution mixture. At the retention times of the
analytes no significant interfering peaks originating from the
placebo sample were noted (Figure 4).
3.2.2. The Limit of Detection (LOD) and Limit of Quantifi-
cation (LOQ). Experimentally determined values of limit of
detection (LOD) and limit of quantification (LOQ) for impu-
rities A, B, C, andDwere defined according to signal-to-noise
ratio (S/N) corresponding to 3 : 1 for LOD and 10 : 1 for LOQ.
The obtained values of LOD were 0.012𝜇g/mL for impurities
A and B (corresponding to 0.012%) and 0.024𝜇g/mL for















































































































































































































































































Figure 3: Plot of coefficients for the response variables: (a) RsA/B and (b) RsC/D.
impurities C and D (corresponding to 0.024%) and of LOQ
0.04 𝜇g/mL for impurities A and B (corresponding to 0.04%)
and 0.08 𝜇g/mL for impurities C and D (corresponding to
0.08%).
3.2.3. Linearity. The calibration curves of peak areas against
concentrations were linear in the investigated range (from
LOQ to 120% of intended test concentration for impurities
A, B, C, and D and from 25–150% for moxonidine) with
correlation coefficients higher than 0.997 (Table 3). Besides,
statistical significance of the intercepts (𝑡) was not higher
than tabular values (𝑡0.05) which confirmed the absence of
interferences (Table 3).
3.2.4. Precision and Accuracy. Theassessment ofmethod pre-
cision was done by calculating the relative standard deviation
(RSD) for each target concentration level.Theobtained values
are presented in Table 4 and fulfilled the required criteria
(RSD 2% for the active substance, 10% for impurities C and
D, and 15% for impurities A and B) [15].
















































































Figure 4: The chromatograms showing the estimation of method selectivity: (a) a chromatogram of placebo solution; (b) a chromatogram
of standard mixture.
Table 3: Statistical data for the calibration curves.
Compound Concentration range (𝜇g/mL) Regression equations 𝑟 𝑡 𝑡 tab (𝑝 = 0.05)
Moxonidine 25–150 𝑦 = 29142.47𝑥 + 94.864 0.9992 1.1968 2.365
Impurity A 0.04–0.6 𝑦 = 24.45681𝑥 − 0.09526 0.9991 0.0607 2.262
Impurity B 0.04–0.6 𝑦 = 27.659𝑥 + 0.1724 0.9976 0.5319 2.262
Impurity C 0.08–1.2 𝑦 = 18.18141𝑥 + 0.1283 0.9982 0.4016 2.262
Impurity D 0.08–1.2 𝑦 = 11.82117𝑥 + 0.1404 0.9976 0.5762 2.262
Table 4: Accuracy and precision of the method.
Compound Concentration level (%) Concentration (𝜇g/mL) Recovery (%) RSD (%)
Moxonidine
80 80 99.04 1.85
100 100 101.15 0.45
120 120 101.54 0.32
Impurity A
LOQ 0.04 95.89 3.79
100 0.5 101.22 0.35
120 0.6 100.51 0.88
Impurity B
LOQ 0.04 97.65 2.92
100 0.5 101.28 0.27
120 0.6 99.19 0.85
Impurity C
LOQ 0.08 95.95 2.02
100 1.0 114.08 0.27
120 1.2 93.82 1.48
Impurity D
LOQ 0.08 93.66 2.09
100 1.0 100.83 0.83
120 1.2 97.77 0.39
The accuracy of the method was evaluated according to
the obtained recovery values (Table 4). For all tested concen-
tration levels obtained recoveries for impurities were in the
range 93.66%–114.08% and for moxonidine 99.04%–101.54%
which meets the requirements for the method accuracy
(98%–102% for active ingredients, 70.0–130.0% for impurities
0.1% < 𝑥 < 0.5%, or 80.0–120.0% for impurities 0.5% < 𝑥 <
1.0%) [15].
3.2.5. Robustness. Robustness is a measure of the capacity
of the method to remain unaffected by small yet deliberate
variations of working conditions, and it is indicative of the
method reliability. ICH Q2 (R1) guideline provides some
recommendations for the factors that should be examined
during robustness testing [13]. In this study, robustness of
the method was estimated by applying small variations of
chromatographic conditions such as column temperature
25±2∘C, flow rate 1.0±0.1mL/min, buffer pH 2.8±0.05, and
the volume ratio of acetonitrile in the mobile phase ±0.5%.
During examination of the robustness one-factor-at-a-time
approachwas applied, whichmeans that one factor is changed
while others were kept on constant level. The highest impact
on chromatographic behavior of tested compounds showed%
of acetonitrile in mobile phase. Finally, all defined variations
in comparison with optimal chromatographic condition did
not affect significantly changes in peak areas (less than 5%),
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retention times (less than 3%), and resolution (less than 3%)
between the tested compounds indicating that method is
robust.
3.2.6. Application of the Method in theMoxogamma 0.4 Tablet
Analysis. In order to confirm the applicability of validated
method, the proposed method was applied in the analysis of
commercially available Moxogamma 0.4 tablet. The obtained
results (97.5% for content of moxonidine, 0.68% for impurity
C, 0.87% for impurityD, and belowLOQvalues for impurities
A and B) were in accordance with manufacture specification
(impuritiesA andBbelow0.5%and impuritiesC andDbelow
1%).
3.3. Advantages of the Method. As noted above, by applying
the HILIC method in which polar silica column was used as
stationary phase complete separation of moxonidine and its
four impurities has been achieved for only 12 minutes. All
tested compounds which are positively charged under the
examined chromatographic conditions accomplished ade-
quate retention which is often difficult to achieve without
the use of ion-pair reagent. In this way the extension of
chromatographic analysis has been avoided, not only in
terms of duration of chromatographic run but also in terms
of column conditioning and washing. Selected temperature
and mobile phase composition are not aggressive and have
favorable influence on the column lifetime. In addition,
validated method is sensitive and enables determination of
impurities present at 0.04% (impurities A and B) and 0.08%
(impurities C and D) level.
4. Conclusion
Retention behavior of moxonidine and its four impurities
has been examined by using a central composite design. The
most important factors and their interactions with a highest
influence on resolution between critical peaks pairs were
determined and optimal chromatographic conditions for sep-
aration of moxonidine and its four impurities were achieved.
The proposed method is selective, linear, accurate, precise,
and robust and has been applied for the determination of
moxonidine and its impurities in the commercially available
pharmaceutical dosage form. The obtained results showed
that content of moxonidine and its four impurities meet the
requirements of manufacturers.
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